[EN] 6-DIFLUOROMETHYL-5,6-DIHYDRO-2H-[1,4]OXAZIN-3-AMINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 6-DIFLUOROMÉTHYL-5,6-DIHYDRO-2H-[1,4]OXAZIN-3-AMINE
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2013083557A1
公开(公告)日:2013-06-13
The invention relates to novel 6-difluoromethyl-5,6-dihydro-2H-[l,4]oxazin-3- amine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebral amyloid angiopathy, multi-infarct dementia, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease and dementia associated with beta-amyloid.
该发明涉及新型的6-二氟甲基-5,6-二氢-2H-[1,4]噁嗪-3-胺衍生物,作为β-分泌酶抑制剂,也被称为β-位点淀粉样蛋白裂解酶、BACE、BACE1、Asp2或memapsin2。该发明还涉及包含这些化合物的药物组合物,用于制备这些化合物和组合物的方法,以及利用这些化合物和组合物预防和治疗涉及β-分泌酶的疾病,如阿尔茨海默病(AD)、轻度认知障碍、老年痴呆、带有Lewy小体的痴呆、脑淀粉样蛋白血管病、多发性梗死性痴呆、唐氏综合症、与中风相关的痴呆、与帕金森病相关的痴呆和与β-淀粉样蛋白相关的痴呆。